Forge Biologics Emphasizes Quality Control Capabilities in Gene Therapy Manufacturing

A LinkedIn post from Forge Biologics highlights the role of its quality control team through a profile of Senior Manager of QC Microbiology and Environmental Monitoring, Jeremy Hynick. The post emphasizes his responsibility for ensuring controlled, qualified environments to support the company’s gene therapy manufacturing activities.

The post suggests that Forge is drawing investor and client attention to its internal capabilities in environmental monitoring and quality systems, key factors in regulated biologics production. For investors, this focus may indicate continuing investment in compliance and operational robustness, which can be important for scaling manufacturing, reducing regulatory risk, and supporting long-term partnership and revenue opportunities in the gene therapy CDMO space.